Summary

Market Insights The market encompasses diagnostic, surgical, and therapeutic devices such as drug-eluting stents, transcatheter heart valves, leadless pacemakers, electrophysiology catheters, and AI-enabled continuous telemetry systems designed to detect, monitor, and treat cardiovascular diseases (CVDs), which remain the leading cause of death worldwide with nearly 18 million lives lost each year. Its critical relevance stems from transforming cardiac clinical pathways by shifting patient treatment from high-risk open-heart surgeries toward minimally invasive transcatheter interventions, significantly lowering perioperative mortality, shortening hospital stays, and reducing long-term healthcare expenditures. Key growth drivers include a rapidly aging global population, rising rates of metabolic comorbidities (such as hypertension, obesity, and diabetes), expanding public health coverage across emerging markets, and continuous technological breakthroughs in miniaturization and remote telecardiology. Essential professional and trade organizations such as the World Heart Federation (WHF), the American Heart Association (AHA), the European Society of Cardiology (ESC), the Asian Pacific Society of Cardiology (APSC), and global medtech coalitions actively support the ecosystem. Their key activities center on defining standardized international treatment guidelines, funding clinical registries, hosting global scientific congresses, providing specialized training for interventional cardiologists, and collaborating with global regulatory bodies (such as the US FDA, European Notified Bodies, Japan's PMDA, and China's NMPA) to harmonize device safety standards and accelerate equitable global access to life-saving cardiac innovations. Encompassing a high-value ecosystem from interventional drug-eluting stents, balloon catheters, and leadless pacemakers to transcatheter heart valves, electrophysiology ablation catheters, and continuous remote monitoring telemetry the market's relevance lies in fundamentally transforming clinical cardiac pathways by shifting care away from open-heart surgical interventions toward minimally invasive transcatheter procedures, drastically reducing patient recovery times, perioperative risks, and hospital stays. According to the research report, “Global Cardiovascular Devices Market Outlook, 2031” published by Bonafide Research, the Global Cardiovascular Devices Market is expected to cross 110.33 Billion market size by 2031, with 8.07% CAGR by 2026-31.. Market expansion is propelled globally by a rapidly aging population, rising global incidence of metabolic risk factors (such as hypertension, obesity, and type-2 diabetes), public health insurance expansions across emerging economies, and rapid technological integration of artificial intelligence (AI) into continuous telemetry and early arrhythmia diagnostic platforms. Key global industry leaders including Medtronic, Abbott Laboratories, Boston Scientific, Edwards Lifesciences, Terumo Corporation, Johnson & Johnson, Biotronik, GE HealthCare, Philips Healthcare, and MicroPort Scientific drive commercial growth through continuous clinical innovation and targeted consolidation, such as Johnson & Johnson's landmark acquisition of Shockwave Medical to advance intravascular lithotripsy. Major global opportunities stem from the rapid adoption of Pulsed Field Ablation (PFA) for atrial fibrillation, expansion of transcatheter mitral and tricuspid valve interventions (TMVR/TTVR), and the migration of low-acuity interventional procedures into ambulatory surgical centers (ASCs). The global ecosystem is anchored by influential medical and trade organizations such as the World Heart Federation (WHF), the American Heart Association (AHA), the European Society of Cardiology (ESC), and regional medtech associations which define clinical treatment standards, maintain international disease registries, fund cardiovascular research, and collaborate with major regulatory bodies (such as the US FDA, European Notified Bodies under EU MDR, Japan's PMDA, China's NMPA, and India's CDSCO) to harmonize approval pathways. Underpinning this entire sector is a highly integrated, multi-tiered global supply chain: upstream inputs rely on specialized raw materials (medical-grade nitinol shape-memory alloys, bioresorbable polymers, platinum-iridium wire, synthetic balloons, and bovine or porcine pericardial tissue); precision manufacturing and cleanroom sub-assembly are concentrated across dedicated global medtech hubs (such as the US, Ireland, Puerto Rico, Germany, Japan, and China); and finished Class III sterile products flow through centralized, cold-chain distribution nodes (such as the Netherlands, Singapore, and the US) directly to hospital catheterization labs worldwide. Despite ongoing commercial challenges including stringent regulatory clearance backlogs, rising compliance costs, and aggressive government pricing controls such as China's Volume-Based Procurement (VBP) the global cardiovascular devices market remains an essential, resilient engine for international medtech innovation and clinical cardiac care. Market Dynamics Market Drivers • Global epidemiological escalation of cardiovascular diseases and population aging: The primary structural engine powering the global cardiovascular devices market is the rising worldwide incidence of cardiovascular diseases (CVDs) including coronary artery disease, heart failure, cardiac arrhythmias, and structural heart defects which collectively cause nearly 18 million deaths annually. This chronic disease burden is exacerbated by a demographic shift, with the global population aged 65 and older expanding at an unprecedented rate across both developed and developing regions. Aging is inherently correlated with progressive vascular stiffness, valvular degeneration, and conduction system disease, creating sustained long-term demand for high-value Class III therapeutic implants (such as transcatheter heart valves, pacemakers, and drug-eluting stents) and advanced diagnostic platforms across healthcare systems globally. • Shift toward minimally invasive transcatheter therapies and outpatient settings: Interventional cardiology is undergoing a fundamental shift away from conventional open-heart surgeries toward minimally invasive transcatheter interventions. Catheter-based techniques significantly lower perioperative mortality, reduce blood loss, minimize surgical trauma, and shorten hospital lengths of stay from weeks to mere days or hours. Simultaneously, health systems and private insurers are actively incentivizing the migration of low-to-moderate acuity interventional procedures (such as diagnostic angiography, intravascular imaging, and uncomplicated stent or rhythm implants) into Ambulatory Surgical Centers (ASCs) and outpatient cardiology clinics. This transition expands procedural throughput and accelerates global procurement of specialized catheter-based delivery systems. Market Challenges • Heightened regulatory scrutiny, compliance costs, and recertification delays: Regulatory authorities worldwide are imposing increasingly rigorous clinical safety standards, raising the barrier to entry for cardiovascular innovation. The ongoing implementation of the European Union Medical Device Regulation (EU MDR 2017/745), alongside heightened post-market surveillance demands from the US FDA, China's NMPA, and Japan's PMDA, requires manufacturers to conduct extensive clinical trials and post-market clinical follow-up (PMCF) studies. Administrative backlogs and capacity constraints among authorized Notified Bodies have led to protracted approval timelines frequently extending commercialization pathways by 18 to 24 months. • Aggressive government pricing controls, tenders, and reimbursement caps: Commercial margins for cardiovascular device manufacturers are under persistent pressure due to cost-containment measures enacted by public healthcare payers globally. Centralized purchasing policies such as China’s National Volume-Based Procurement (VBP) scheme, India’s national price ceilings on coronary stents, and rigid Health Technology Assessments (HTA) across European public single-payer systems have forced deep price reductions on high-volume product categories like drug-eluting stents, balloon catheters, and cardiac pacemakers. Furthermore, restrictive private insurance reimbursement ceilings and delayed claim settlements hinder hospital adoption of costly next-generation implants, creating commercial friction for innovative devices. Market Trends • Rapid paradigm shift to pulsed field ablation (PFA) in electrophysiology: Electrophysiology is witnessing a rapid clinical transition from traditional thermal ablation methods (radiofrequency thermal energy and cryoablation) toward Pulsed Field Ablation (PFA) for treating atrial fibrillation. PFA utilizes non-thermal tissue-selective irreversible electroporation to ablate arrhythmogenic cardiac tissue while sparing adjacent critical structures, such as the esophagus, phrenic nerve, and coronary arteries. The rapid clinical adoption and regulatory clearances of major PFA platforms such as Boston Scientific’s Farapulse, Medtronic’s PulseSelect, and Biosense Webster’s VARIPULSE are dramatically reducing procedure times, improving patient safety profiles, and capturing substantial market share in the global electrophysiology segment. • Integration of artificial intelligence and connected telecardiology ecosystems: Diagnostic and continuous cardiac monitoring devices are rapidly evolving from standalone signal-recording hardware into AI-integrated, cloud-connected digital platforms. Deep-learning algorithms are now directly embedded into implantable loop recorders, smart wearables, ECG systems, and remote telemetry networks to automatically analyze complex cardiac waveforms, predict early heart failure decompensation, and filter out false-positive arrhythmia alerts with high sensitivity. This shift toward connected telecardiology allows clinical care teams to monitor high-risk chronic cardiac patients in real time outside traditional hospital settings, optimizing physician workflows, enabling early preventive care, and reducing acute emergency readmissions. Market Segments Therapeutic and surgical devices are the largest device-type segment because cardiovascular treatment frequently requires direct intervention through stents, catheters, pacemakers, valves, vascular grafts, and other technologies that restore blood flow, correct structural abnormalities, or support cardiac function. Therapeutic and surgical cardiovascular devices occupy a central position in global cardiac care because they are used when cardiovascular disease requires an intervention beyond diagnosis or routine medication. Cardiovascular diseases remain the world's leading cause of death, with WHO estimating 19.8 million deaths from CVDs in 2022, and heart attacks and strokes accounting for approximately 85% of these deaths. This large clinical burden creates continuing demand for technologies capable of directly treating diseased vessels, abnormal rhythms, weakened cardiac function, and damaged heart valves. The FDA identifies a broad group of cardiovascular devices used in clinical practice, including catheters, coronary and vascular stents, artificial heart valves, ventricular-assist devices, endovascular grafts, pacemakers, defibrillators, mapping systems, and ablation catheters. This breadth is important because therapeutic and surgical devices address several different cardiovascular conditions rather than being limited to one disease. For coronary artery disease, angioplasty balloons, guidewires, drug-eluting stents, and catheter systems can be used to restore or maintain blood flow. For rhythm disorders, pacemakers and implantable cardioverter-defibrillators can regulate or respond to abnormal electrical activity. For structural disease, surgical and transcatheter heart valves can replace or treat dysfunctional valves. Ventricular-assist devices can provide mechanical circulatory support for selected patients with severe heart failure. The FDA's cardiovascular-device research program also focuses on hemocompatibility, hemodynamics, durability, and electrophysiology, reflecting the technically demanding nature of these devices and their direct interaction with blood, cardiac tissue, and electrical activity. Technological development is further expanding the therapeutic role of these devices through minimally invasive procedures that can reduce surgical trauma and recovery requirements for appropriately selected patients. Regulatory standards also cover transcatheter and surgically implanted heart valves, vascular stents, pacemakers, invasive blood-pressure monitors, and other cardiovascular technologies, demonstrating the breadth of established device applications. Coronary artery disease is the largest application segment because coronary atherosclerosis and acute coronary events generate extensive need for diagnostic angiography, angioplasty, stenting, revascularization, and related cardiovascular interventions worldwide. Coronary artery disease has a particularly strong connection with cardiovascular device utilization because the disease directly affects the arteries responsible for supplying blood to the heart muscle and can progress to severe obstruction, myocardial ischemia, heart attack, and other complications. WHO classifies coronary heart disease among the major cardiovascular diseases and explains that heart attacks commonly result from blockages that prevent adequate blood flow to the heart. The disease pathway creates a direct requirement for several types of cardiovascular technology. Clinicians may use electrocardiography and imaging to evaluate suspected disease, coronary angiography to identify arterial narrowing, and catheter-based systems to restore blood flow when intervention is appropriate. Percutaneous coronary intervention can involve guidewires, balloons, drug-eluting stents, imaging catheters, pressure-measurement technologies, and other specialized equipment. Patients with complex coronary anatomy may instead require coronary artery bypass surgery, which brings additional surgical devices and hospital technologies into the treatment pathway. The global relevance of coronary artery disease is reinforced by the overall cardiovascular burden. WHO reports that CVDs caused approximately 19.8 million deaths in 2022 and identifies heart attacks and strokes as responsible for the large majority of cardiovascular deaths. Risk factors such as high blood pressure, elevated blood glucose, abnormal blood lipids, obesity, physical inactivity, tobacco use, and unhealthy diets contribute to cardiovascular disease development and are measurable in primary-care settings. This means coronary disease creates demand across the entire healthcare pathway, from prevention and risk assessment to diagnosis, acute intervention, revascularization, and long-term follow-up. Device innovation has also broadened the ability to treat complex coronary lesions. The FDA regulates coronary and vascular stents, catheters, and related cardiovascular technologies and conducts research into issues such as thrombosis, blood-device interaction, hemodynamics, and device durability. Hospitals and cardiac care centers are the largest end-user segment because advanced cardiovascular procedures require specialized catheterization laboratories, operating rooms, intensive monitoring, imaging, emergency support, and multidisciplinary cardiac teams that are concentrated in these facilities. Hospitals and dedicated cardiac care centers represent the principal setting for cardiovascular-device utilization because many cardiovascular technologies require specialized infrastructure and trained personnel to be used safely and effectively. Cardiovascular devices can range from relatively simple monitoring systems to complex implantable technologies that interact directly with blood vessels, cardiac tissue, or the heart's electrical system. The FDA lists catheters, stents, artificial heart valves, ventricular-assist devices, pacemakers, defibrillators, endovascular grafts, mapping systems, and ablation catheters among cardiovascular technologies used for diagnosis and treatment. Many of these devices are deployed in hospitals because procedures such as coronary angiography, percutaneous coronary intervention, electrophysiology studies, ablation, valve replacement, cardiac surgery, and mechanical circulatory support require controlled clinical environments. A catheterization laboratory, for example, combines specialized imaging, monitoring, sterile procedural equipment, and emergency capabilities so physicians can diagnose and treat cardiovascular problems within the same episode of care. Complex procedures also require immediate access to anesthesia, intensive care, surgery, blood products, and resuscitation equipment if complications occur. This makes hospitals particularly important compared with healthcare settings that provide only routine consultations or basic screening. The technical demands of cardiovascular devices further reinforce the role of specialist facilities. FDA regulatory-science research addresses hemocompatibility, thrombosis, hemodynamic performance, durability, mechanical fatigue, corrosion, and electrophysiology because cardiovascular implants and instruments must function reliably under demanding physiological conditions. Hospitals also provide the post-procedure observation required for patients receiving implanted devices or undergoing invasive cardiovascular treatment. Cardiac centers can maintain specialized teams consisting of interventional cardiologists, cardiac surgeons, electrophysiologists, anesthesiologists, imaging specialists, nurses, and cardiovascular technicians. Regional Insights North America is the largest region because it combines a substantial cardiovascular disease burden with advanced healthcare infrastructure, high availability of specialized cardiac procedures, strong medical-device innovation, and mature regulatory and clinical ecosystems. North America's position in the global cardiovascular-device landscape is supported by the scale and sophistication of its healthcare systems, particularly in the United States and Canada. Cardiovascular disease remains a major health concern in the United States, where the FDA states that heart disease is the leading cause of death among adults and that FDA-approved devices such as pacemakers and defibrillators have improved the lives of millions of people with heart disease. The region also has a highly developed network of hospitals, cardiovascular centers, catheterization laboratories, electrophysiology units, cardiac surgery facilities, and specialized imaging services capable of adopting sophisticated devices. This infrastructure supports the use of coronary stents, ablation systems, implantable rhythm devices, artificial heart valves, ventricular-assist devices, vascular grafts, and advanced monitoring technologies. The United States also has a mature regulatory framework through the FDA's Center for Devices and Radiological Health, which conducts dedicated cardiovascular regulatory-science research to support access to innovative devices while evaluating their safety and effectiveness. Its research activities cover hemocompatibility, hemodynamics, device durability, and electrophysiology, areas that are particularly important for cardiovascular implants and interventional technologies. • USA: The United States is the largest regional segment because it combines a very large cardiovascular disease burden with extensive hospital infrastructure, advanced cardiac-care capabilities, and broad clinical adoption enabled many patients to live longer with chronic cardiovascular conditions. The American Heart Association states that heart disease has remained the leading cause of death in the United States for more than a century, while advances in prevention and treatment have reduced deaths from heart attacks and enabled many patients to live longer with chronic cardiovascular conditions. The country also has extensive clinical infrastructure dedicated to cardiovascular care, including hospitals, catheterization laboratories, cardiac surgery units, electrophysiology services, imaging facilities, and specialized cardiac centers. Key Devlopments • July 2026: Johnson & Johnson announced FDA approval of the Dual Energy THERMOCOOL SMARTTOUCH SF Platform for delivering both radiofrequency and pulsed field energy. The approval advances dual-energy ablation in electrophysiology and strengthens platform-based selling when paired with mapping and workflow tools. • March 2026: BIOTRONIK announced the launch of its pivotal BIO‑LivIQ study to evaluate the LivIQ leadless pacemaker, which is a next‑generation device designed to deliver AV‑synchrony using advanced far‑field sensing. The trial will enroll 325 patients across 60 sites worldwide, assessing safety, pacing performance, and synchrony. • December 2025: Impulse Dynamics raised more than USD 158 million in funding to accelerate commercialization, clinical trials, and development of its heart failure technologies, including CCM therapy. The investment will significantly improve access to CCM therapy for patients and validate its clinical effectiveness. • December 2025: Philips announced the acquisition of SpectraWAVE Inc., bringing next‑generation AI‑powered coronary intravascular imaging and physiology assessment into its portfolio. • September 2025: Philips launched a cardiac monitoring telemetry platform to tackle staff shortages and alarm management, featuring the Telemetry Monitor 5500, an integrated central unit that works seamlessly with the platform. • August 2025: BDC Laboratories collaborated with the Dilawri Cardiovascular Institute (DCI) to advance the development and clinical validation of cardiovascular medical devices. • July 2025: for early diagnosis of signs of cardiovascular stress, an Artificial Intelligence (AI)-driven device (MyoBioScan) was developed by the Karnataka State Open University (KSOU), Mysuru. Alerts are provided to the users by this wearable patch about the potential heart-related issues, as it monitors the cardiovascular health. (Source - The Hindu) • July 2025: to revolutionize remote cardiac care and to amplify OMRON’s ‘Going for Zero’ vision of a world with zero cardiovascular events, an advanced connected health platform, that is KeeboHealth, will be launched by the collaboration between OMRON Healthcare and Tricog Health, which is an AI-driven cardiac care company, was announced. • January 2025: CMS issued a National Coverage Determination approving implantable pulmonary artery pressure sensors for heart failure management under coverage with evidence development. This decision allows Medicare beneficiaries, including those previously denied under Medicare Advantage, to access the CardioMEMS HF System. • January 2025: Boston Scientific completed the Bolt Medical acquisition for USD 664 million, broadening its intravascular lithotripsy franchise and expanding coverage in coronary and peripheral interventions. • April 2024: Johnson & Johnson completed its acquisition of Shockwave Medical for USD 13.1 billion, adding a scaled intravascular lithotripsy franchise with broad procedural adoption. • June 2024: Abbott today announced it has received CE Mark in Europe for the AVEIR™ dual chamber (DR) leadless pacemaker system, the world's first dual chamber leadless pacemaker that treats people with abnormal or slow heart rhythms. The AVEIR DR leadless pacemaker system utilizes a new method of delivering dual chamber therapy as it is comprised of two unique devices – one that paces the right ventricle (AVEIR VR) and one that paces the right atrium (AVEIR AR). Considered in this report • Historic Year: 2020 • Base year: 2025 • Estimated year: 2026 • Forecast year: 2031 Aspects covered in this report • Cardiovascular Devices Market with its value and forecast along with its segments • Various drivers and challenges • On-going trends and developments • Top profiled companies • Strategic recommendation By Device Type • Therapeutic and Surgical Devices • Diagnostic and Monitoring Devices By Application • Coronary Artery Disease (CAD) • Heart Failure • Cardiac Arrhythmia • Structural Heart Disease • Other Applications By End User • Hospitals & Cardiac Centers • Ambulatory Surgical Centers (ASCs) • Specialty Clinics • Home-Care Settings ***Please Note: It will take 48 hours (2 Business days) for delivery of the report upon order confirmation.

ページTOPに戻る

Table of Contents

Table of Content

1. Executive Summary
2. Market Dynamics
2.1. Market Drivers & Opportunities
2.2. Market Restraints & Challenges
2.3. Market Trends
2.4. Supply chain Analysis
2.5. Policy & Regulatory Framework
2.6. Industry Experts Views
3. Research Methodology
3.1. Secondary Research
3.2. Primary Data Collection
3.3. Market Formation & Validation
3.4. Report Writing, Quality Check & Delivery
4. Market Structure
4.1. Market Considerate
4.2. Assumptions
4.3. Limitations
4.4. Abbreviations
4.5. Sources
4.6. Definitions
5. Economic /Demographic Snapshot
6. Global Cardiovascular Devices Market Outlook
6.1. Market Size By Value
6.2. Market Share By Region
6.3. Market Size and Forecast, By Geography
6.4. Market Size and Forecast, By Device Type
6.4.1. Market Size and Forecast, By Therapeutic and Surgical Devices
6.4.2. Market Size and Forecast, By Diagnostic and Monitoring Devices
6.5. Market Size and Forecast, By Application
6.6. Market Size and Forecast, By End User
7. North America Cardiovascular Devices Market Outlook
7.1. Market Size By Value
7.2. Market Share By Country
7.3. Market Size and Forecast, By Device Type
7.4. Market Size and Forecast, By Application
7.5. Market Size and Forecast, By End User
7.6. United States Cardiovascular Devices Market Outlook
7.6.1. Market Size by Value
7.6.2. Market Size and Forecast By Device Type
7.6.3. Market Size and Forecast By Application
7.6.4. Market Size and Forecast By End User
7.7. Canada Cardiovascular Devices Market Outlook
7.7.1. Market Size by Value
7.7.2. Market Size and Forecast By Device Type
7.7.3. Market Size and Forecast By Application
7.7.4. Market Size and Forecast By End User
7.8. Mexico Cardiovascular Devices Market Outlook
7.8.1. Market Size by Value
7.8.2. Market Size and Forecast By Device Type
7.8.3. Market Size and Forecast By Application
7.8.4. Market Size and Forecast By End User
8. Europe Cardiovascular Devices Market Outlook
8.1. Market Size By Value
8.2. Market Share By Country
8.3. Market Size and Forecast, By Device Type
8.4. Market Size and Forecast, By Application
8.5. Market Size and Forecast, By End User
8.6. Germany Cardiovascular Devices Market Outlook
8.6.1. Market Size by Value
8.6.2. Market Size and Forecast By Device Type
8.6.3. Market Size and Forecast By Application
8.6.4. Market Size and Forecast By End User
8.7. United Kingdom (UK) Cardiovascular Devices Market Outlook
8.7.1. Market Size by Value
8.7.2. Market Size and Forecast By Device Type
8.7.3. Market Size and Forecast By Application
8.7.4. Market Size and Forecast By End User
8.8. France Cardiovascular Devices Market Outlook
8.8.1. Market Size by Value
8.8.2. Market Size and Forecast By Device Type
8.8.3. Market Size and Forecast By Application
8.8.4. Market Size and Forecast By End User
8.9. Italy Cardiovascular Devices Market Outlook
8.9.1. Market Size by Value
8.9.2. Market Size and Forecast By Device Type
8.9.3. Market Size and Forecast By Application
8.9.4. Market Size and Forecast By End User
8.10. Spain Cardiovascular Devices Market Outlook
8.10.1. Market Size by Value
8.10.2. Market Size and Forecast By Device Type
8.10.3. Market Size and Forecast By Application
8.10.4. Market Size and Forecast By End User
8.11. Russia Cardiovascular Devices Market Outlook
8.11.1. Market Size by Value
8.11.2. Market Size and Forecast By Device Type
8.11.3. Market Size and Forecast By Application
8.11.4. Market Size and Forecast By End User
9. Asia-Pacific Cardiovascular Devices Market Outlook
9.1. Market Size By Value
9.2. Market Share By Country
9.3. Market Size and Forecast, By Device Type
9.4. Market Size and Forecast, By Application
9.5. Market Size and Forecast, By End User
9.6. China Cardiovascular Devices Market Outlook
9.6.1. Market Size by Value
9.6.2. Market Size and Forecast By Device Type
9.6.3. Market Size and Forecast By Application
9.6.4. Market Size and Forecast By End User
9.7. Japan Cardiovascular Devices Market Outlook
9.7.1. Market Size by Value
9.7.2. Market Size and Forecast By Device Type
9.7.3. Market Size and Forecast By Application
9.7.4. Market Size and Forecast By End User
9.8. India Cardiovascular Devices Market Outlook
9.8.1. Market Size by Value
9.8.2. Market Size and Forecast By Device Type
9.8.3. Market Size and Forecast By Application
9.8.4. Market Size and Forecast By End User
9.9. Australia Cardiovascular Devices Market Outlook
9.9.1. Market Size by Value
9.9.2. Market Size and Forecast By Device Type
9.9.3. Market Size and Forecast By Application
9.9.4. Market Size and Forecast By End User
9.10. South Korea Cardiovascular Devices Market Outlook
9.10.1. Market Size by Value
9.10.2. Market Size and Forecast By Device Type
9.10.3. Market Size and Forecast By Application
9.10.4. Market Size and Forecast By End User
10. South America Cardiovascular Devices Market Outlook
10.1. Market Size By Value
10.2. Market Share By Country
10.3. Market Size and Forecast, By Device Type
10.4. Market Size and Forecast, By Application
10.5. Market Size and Forecast, By End User
10.6. Brazil Cardiovascular Devices Market Outlook
10.6.1. Market Size by Value
10.6.2. Market Size and Forecast By Device Type
10.6.3. Market Size and Forecast By Application
10.6.4. Market Size and Forecast By End User
10.7. Argentina Cardiovascular Devices Market Outlook
10.7.1. Market Size by Value
10.7.2. Market Size and Forecast By Device Type
10.7.3. Market Size and Forecast By Application
10.7.4. Market Size and Forecast By End User
10.8. Colombia Cardiovascular Devices Market Outlook
10.8.1. Market Size by Value
10.8.2. Market Size and Forecast By Device Type
10.8.3. Market Size and Forecast By Application
10.8.4. Market Size and Forecast By End User
11. Middle East & Africa Cardiovascular Devices Market Outlook
11.1. Market Size By Value
11.2. Market Share By Country
11.3. Market Size and Forecast, By Device Type
11.4. Market Size and Forecast, By Application
11.5. Market Size and Forecast, By End User
11.6. United Arab Emirates (UAE) Cardiovascular Devices Market Outlook
11.6.1. Market Size by Value
11.6.2. Market Size and Forecast By Device Type
11.6.3. Market Size and Forecast By Application
11.6.4. Market Size and Forecast By End User
11.7. Saudi Arabia Cardiovascular Devices Market Outlook
11.7.1. Market Size by Value
11.7.2. Market Size and Forecast By Device Type
11.7.3. Market Size and Forecast By Application
11.7.4. Market Size and Forecast By End User
11.8. South Africa Cardiovascular Devices Market Outlook
11.8.1. Market Size by Value
11.8.2. Market Size and Forecast By Device Type
11.8.3. Market Size and Forecast By Application
11.8.4. Market Size and Forecast By End User
12. Competitive Landscape
12.1. Competitive Dashboard
12.2. Business Strategies Adopted by Key Players
12.3. Key Players Market Share Insights and Analysis, 2025
12.4. Key Players Market Positioning Matrix
12.5. Porter's Five Forces
12.6. Company Profile
12.6.1. Medtronic
12.6.1.1. Company Snapshot
12.6.1.2. Company Overview
12.6.1.3. Financial Highlights
12.6.1.4. Geographic Insights
12.6.1.5. Business Segment & Performance
12.6.1.6. Product Portfolio
12.6.1.7. Key Executives
12.6.1.8. Strategic Moves & Developments
12.6.2. Abbott
12.6.3. Boston Scientific Corporation
12.6.4. Terumo Corporation
12.6.5. B. Braun SE
12.6.6. Koninklijke Philips N.V.
12.6.7. GE Healthcare Technologies, Inc
12.6.8. BIOTRONIK SE & Co. KG
12.6.9. Edwards Lifesciences Corporation
12.6.10. Siemens Healthineers
12.6.11. Baxter International Inc
12.6.12. Johnson & Johnson
12.6.13. Nihon Kohden Corporation
12.6.14. Getinge AB
12.6.15. MicroPort Scientific Corporation
12.6.16. AngioDynamics, Inc.
12.6.17. Artivion Inc
12.6.18. Sahajanand Medical Technologies Limited
12.6.19. W.L. Gore & Associates, Inc
12.6.20. Lepu Medical Technology
13. Strategic Recommendations
14. Annexure
14.1. FAQ`s
14.2. Notes
15. Disclaimer

ページTOPに戻る

List of Tables/Graphs

List of Figures

Figure 1: Global Cardiovascular Devices Market Size (USD Billion) By Region, 2025 & 2031F
Figure 2: Market attractiveness Index, By Region 2031F
Figure 3: Market attractiveness Index, By Segment 2031F
Figure 4: Global Cardiovascular Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 5: Global Cardiovascular Devices Market Share By Region (2025)
Figure 6: North America Cardiovascular Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 7: North America Cardiovascular Devices Market Share By Country (2025)
Figure 8: US Cardiovascular Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 9: Canada Cardiovascular Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 10: Mexico Cardiovascular Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 11: Europe Cardiovascular Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 12: Europe Cardiovascular Devices Market Share By Country (2025)
Figure 13: Germany Cardiovascular Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 14: United Kingdom (UK) Cardiovascular Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 15: France Cardiovascular Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 16: Italy Cardiovascular Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 17: Spain Cardiovascular Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 18: Russia Cardiovascular Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 19: Asia-Pacific Cardiovascular Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 20: Asia-Pacific Cardiovascular Devices Market Share By Country (2025)
Figure 21: China Cardiovascular Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 22: Japan Cardiovascular Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 23: India Cardiovascular Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 24: Australia Cardiovascular Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 25: South Korea Cardiovascular Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 26: South America Cardiovascular Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 27: South America Cardiovascular Devices Market Share By Country (2025)
Figure 28: Brazil Cardiovascular Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 29: Argentina Cardiovascular Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 30: Colombia Cardiovascular Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 31: Middle East & Africa Cardiovascular Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 32: Middle East & Africa Cardiovascular Devices Market Share By Country (2025)
Figure 33: United Arab Emirates (UAE) Cardiovascular Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 34: Saudi Arabia Cardiovascular Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 35: South Africa Cardiovascular Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 36: Porter's Five Forces of Global Cardiovascular Devices Market


List of Tables

Table 1: Global Cardiovascular Devices Market Snapshot, By Segmentation (2025 & 2031F) (in USD Billion)
Table 2: Influencing Factors for Cardiovascular Devices Market, 2025
Table 3: Top 10 Counties Economic Snapshot 2024
Table 4: Economic Snapshot of Other Prominent Countries 2022
Table 5: Average Exchange Rates for Converting Foreign Currencies into U.S. Dollars
Table 6: Global Cardiovascular Devices Market Size and Forecast, By Geography (2020 to 2031F) (In USD Billion)
Table 7: Global Cardiovascular Devices Market Size and Forecast, By Device Type (2020 to 2031F) (In USD Billion)
Table 8: Global Cardiovascular Devices Market Size and Forecast, By Therapeutic and Surgical Devices (2020 to 2031F) (In USD Billion)
Table 9: Global Cardiovascular Devices Market Size and Forecast, By Diagnostic and Monitoring Devices (2020 to 2031F) (In USD Billion)
Table 10: Global Cardiovascular Devices Market Size and Forecast, By Application (2020 to 2031F) (In USD Billion)
Table 11: Global Cardiovascular Devices Market Size and Forecast, By End User (2020 to 2031F) (In USD Billion)
Table 12: North America Cardiovascular Devices Market Size and Forecast, By Device Type (2020 to 2031F) (In USD Billion)
Table 13: North America Cardiovascular Devices Market Size and Forecast, By Application (2020 to 2031F) (In USD Billion)
Table 14: North America Cardiovascular Devices Market Size and Forecast, By End User (2020 to 2031F) (In USD Billion)
Table 15: United States Cardiovascular Devices Market Size and Forecast By Device Type (2020 to 2031F) (In USD Billion)
Table 16: United States Cardiovascular Devices Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 17: United States Cardiovascular Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 18: Canada Cardiovascular Devices Market Size and Forecast By Device Type (2020 to 2031F) (In USD Billion)
Table 19: Canada Cardiovascular Devices Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 20: Canada Cardiovascular Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 21: Mexico Cardiovascular Devices Market Size and Forecast By Device Type (2020 to 2031F) (In USD Billion)
Table 22: Mexico Cardiovascular Devices Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 23: Mexico Cardiovascular Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 24: Europe Cardiovascular Devices Market Size and Forecast, By Device Type (2020 to 2031F) (In USD Billion)
Table 25: Europe Cardiovascular Devices Market Size and Forecast, By Application (2020 to 2031F) (In USD Billion)
Table 26: Europe Cardiovascular Devices Market Size and Forecast, By End User (2020 to 2031F) (In USD Billion)
Table 27: Germany Cardiovascular Devices Market Size and Forecast By Device Type (2020 to 2031F) (In USD Billion)
Table 28: Germany Cardiovascular Devices Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 29: Germany Cardiovascular Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 30: United Kingdom (UK) Cardiovascular Devices Market Size and Forecast By Device Type (2020 to 2031F) (In USD Billion)
Table 31: United Kingdom (UK) Cardiovascular Devices Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 32: United Kingdom (UK) Cardiovascular Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 33: France Cardiovascular Devices Market Size and Forecast By Device Type (2020 to 2031F) (In USD Billion)
Table 34: France Cardiovascular Devices Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 35: France Cardiovascular Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 36: Italy Cardiovascular Devices Market Size and Forecast By Device Type (2020 to 2031F) (In USD Billion)
Table 37: Italy Cardiovascular Devices Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 38: Italy Cardiovascular Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 39: Spain Cardiovascular Devices Market Size and Forecast By Device Type (2020 to 2031F) (In USD Billion)
Table 40: Spain Cardiovascular Devices Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 41: Spain Cardiovascular Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 42: Russia Cardiovascular Devices Market Size and Forecast By Device Type (2020 to 2031F) (In USD Billion)
Table 43: Russia Cardiovascular Devices Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 44: Russia Cardiovascular Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 45: Asia-Pacific Cardiovascular Devices Market Size and Forecast, By Device Type (2020 to 2031F) (In USD Billion)
Table 46: Asia-Pacific Cardiovascular Devices Market Size and Forecast, By Application (2020 to 2031F) (In USD Billion)
Table 47: Asia-Pacific Cardiovascular Devices Market Size and Forecast, By End User (2020 to 2031F) (In USD Billion)
Table 48: China Cardiovascular Devices Market Size and Forecast By Device Type (2020 to 2031F) (In USD Billion)
Table 49: China Cardiovascular Devices Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 50: China Cardiovascular Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 51: Japan Cardiovascular Devices Market Size and Forecast By Device Type (2020 to 2031F) (In USD Billion)
Table 52: Japan Cardiovascular Devices Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 53: Japan Cardiovascular Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 54: India Cardiovascular Devices Market Size and Forecast By Device Type (2020 to 2031F) (In USD Billion)
Table 55: India Cardiovascular Devices Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 56: India Cardiovascular Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 57: Australia Cardiovascular Devices Market Size and Forecast By Device Type (2020 to 2031F) (In USD Billion)
Table 58: Australia Cardiovascular Devices Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 59: Australia Cardiovascular Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 60: South Korea Cardiovascular Devices Market Size and Forecast By Device Type (2020 to 2031F) (In USD Billion)
Table 61: South Korea Cardiovascular Devices Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 62: South Korea Cardiovascular Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 63: South America Cardiovascular Devices Market Size and Forecast, By Device Type (2020 to 2031F) (In USD Billion)
Table 64: South America Cardiovascular Devices Market Size and Forecast, By Application (2020 to 2031F) (In USD Billion)
Table 65: South America Cardiovascular Devices Market Size and Forecast, By End User (2020 to 2031F) (In USD Billion)
Table 66: Brazil Cardiovascular Devices Market Size and Forecast By Device Type (2020 to 2031F) (In USD Billion)
Table 67: Brazil Cardiovascular Devices Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 68: Brazil Cardiovascular Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 69: Argentina Cardiovascular Devices Market Size and Forecast By Device Type (2020 to 2031F) (In USD Billion)
Table 70: Argentina Cardiovascular Devices Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 71: Argentina Cardiovascular Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 72: Colombia Cardiovascular Devices Market Size and Forecast By Device Type (2020 to 2031F) (In USD Billion)
Table 73: Colombia Cardiovascular Devices Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 74: Colombia Cardiovascular Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 75: Middle East & Africa Cardiovascular Devices Market Size and Forecast, By Device Type (2020 to 2031F) (In USD Billion)
Table 76: Middle East & Africa Cardiovascular Devices Market Size and Forecast, By Application (2020 to 2031F) (In USD Billion)
Table 77: Middle East & Africa Cardiovascular Devices Market Size and Forecast, By End User (2020 to 2031F) (In USD Billion)
Table 78: United Arab Emirates (UAE) Cardiovascular Devices Market Size and Forecast By Device Type (2020 to 2031F) (In USD Billion)
Table 79: United Arab Emirates (UAE) Cardiovascular Devices Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 80: United Arab Emirates (UAE) Cardiovascular Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 81: Saudi Arabia Cardiovascular Devices Market Size and Forecast By Device Type (2020 to 2031F) (In USD Billion)
Table 82: Saudi Arabia Cardiovascular Devices Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 83: Saudi Arabia Cardiovascular Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 84: South Africa Cardiovascular Devices Market Size and Forecast By Device Type (2020 to 2031F) (In USD Billion)
Table 85: South Africa Cardiovascular Devices Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 86: South Africa Cardiovascular Devices Market Size and Forecast By End User (2020 to 2031F) (In USD Billion)
Table 87: Competitive Dashboard of top 5 players, 2025
Table 88: Key Players Market Share Insights and Analysis for Cardiovascular Devices Market 2025